Cooper Companies, Inc. v. Transcontinental Insurance

31 Cal. App. 4th 1094, 37 Cal. Rptr. 2d 508, 95 Daily Journal DAR 1109, 95 Cal. Daily Op. Serv. 652, 1995 Cal. App. LEXIS 48
CourtCalifornia Court of Appeal
DecidedJanuary 24, 1995
DocketA064522
StatusPublished
Cited by61 cases

This text of 31 Cal. App. 4th 1094 (Cooper Companies, Inc. v. Transcontinental Insurance) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cooper Companies, Inc. v. Transcontinental Insurance, 31 Cal. App. 4th 1094, 37 Cal. Rptr. 2d 508, 95 Daily Journal DAR 1109, 95 Cal. Daily Op. Serv. 652, 1995 Cal. App. LEXIS 48 (Cal. Ct. App. 1995).

Opinion

Opinion

HAERLE, J.

I. Introduction

This is an appeal from a declaratory judgment entered in favor of the insurer, respondent Transcontinental Insurance Company (Transcontinental), and against the insured, appellant The Cooper Companies, Inc. The trial court held that two liability insurance policies issued to Cooper Laboratories (Cooper Labs), and its wholly owned subsidiary, CooperVision (later renamed The Cooper Companies; hereafter sometimes Cooper) by Transcontinental from July 1, 1982, to August 1, 1985 (policy period) did not provide coverage 1 to Cooper and two of its subsidiaries, which were acquired after the expiration of the policy period, for bodily injury claims arising during the policy period alleged to have been caused by breast implants manufactured and distributed by the two subsidiaries. We affirm the judgment.

II. Factual and Procedural Background

Cooper Labs was a Palo Alto-based company that, in the early 1980’s, manufactured and sold various medical and dental drugs, devices and diagnostics. During that period, it also pursued a policy of acquiring and divesting itself of businesses that developed and/or marketed other such products, as well as ophthalmic and orthopedic devices, birth control devices and surgical lasers. In March of 1980, it consolidated some of its product lines into a new subsidiary, CooperVision, Inc., which in 1987 was renamed The Cooper Companies, Inc. Cooper Labs “spun off’ CooperVision to its shareholders in 1983, after which the latter became, and was operated as, an independent entity. Cooper Labs continued its “spin off’ and sale strategy and eventually dissolved in 1985. Thereafter, CooperVision adopted its parent company’s strategy of buying and selling various businesses manufacturing and marketing medical and dental devices and products.

Effective July 1, 1982, and continuing for a little over three years thereafter, until August 1, 1985, Transcontinental issued to Cooper Labs and *1098 CooperVision the two occurrence liability insurance policies at issue here (sometimes hereafter jointly referred to as the policies). 2 The first policy is entitled Special Excess Liability Policy — Excess Products and Completed Operations Only (products policy); it provides $50,000 coverage per occurrence over a $1 million retained limit with total payment limited to $50,000 during each policy year. The second policy is entitled Commercial Umbrella Liability Policy (umbrella policy), which provides $10 million of products liability coverage per policy year, under two separate insuring agreements: (a) coverage A, which provides “following form” excess coverage on top of the products policy; and (b) coverage B, which provides umbrella coverage in excess of a $10,000 retention for claims that fall within the umbrella policy’s own insuring agreement, but are not covered by the products policy.

Because Cooper Labs desired to minimize any potential gaps in coverage that could arise in light of its strategy of buying and selling companies, as originally drafted both policies contained a named insured endorsement that was, at least in one respect, unusual; it stated that “[t]he named insured, of the declarations shall read: Cooper Laboratories, Inc., and any organization, association or business entity now existing or hereafter a[c]quired, in which Cooper Laboratories, Inc. owns an interest of fifty percent (50%) or more over which Cooper Laboratories, Inc. ex[]ercises active management and control. Such organization, association or entity as described herein shall include subsidiary or organizations standing in like relationship to such organization, association or entity, and shall include any employee club or association which is sponsored or approved by the management of Cooper Laboratories, Inc.” The unusual feature of this endorsement, at least as compared to industry practice as established in the court below, was the broadening of the named insured coverage by the inclusion of the words “or hereafter acquired” without the inclusion of any further temporal limitation.

In 1987, almost two years after both policies had expired, and also two years after the original insured, Cooper Labs, had dissolved, Cooper acquired two companies, Natural Y Surgical Specialties, Inc. (Natural Y) and Aesthetech Corporation (Aesthetech), both of which manufactured and sold breast implants. Cooper divested itself of these companies in 1988 but, in the process, retained their liabilities. 3 Prior to the 1988 sale, neither of these briefly held subsidiaries of Cooper had experienced much exposure to breast *1099 implant claims. This situation started to change in 1990 and, by 1993, over 1,400 lawsuits were on file against Cooper or one or both of the two subsidiaries. One of these lawsuits resulted in a $4.5 million jury verdict in New York state court, shortly after which Cooper tendered to Transcontinental the defense of the breast implant claims against it or either subsidiary arising during the policy period. Transcontinental denied coverage and this declaratory relief action ensued.

The parties commendably stipulated to much that expedited the trial and this appeal. First of all, they stipulated to bifurcate the trial into two phases, phase I to address the issue of whether the policies, with their “after acquired” language, provided coverage to Cooper or either subsidiary, and phase II to address other coverage issues. The parties agreed that there would be no need to proceed to phase II if Transcontinental prevailed in phase I. The parties also stipulated to many basic background facts and assumptions, including that some or all of the bodily injury alleged in the breast implant suits occurred during the policy period and that Cooper has exhausted its retention requirements under the policies.

The case was tried over three trial days to the court, sitting without a jury. On October 5,1993, the court issued a statement of tentative decision which, with minor modifications, became final in December of that year. The trial court concluded that the “hereafter acquired” language in the named insured endorsement was ambiguous, but that an insured who purchased the policies would have an objectively reasonable expectation only for coverage of companies acquired during the policy period. The court therefore held as a matter of law that the policies do not provide coverage for Natural Y and Aesthetech or for Cooper’s liability for the tortious conduct of these two subsidiaries. 4

III. Discussion

A. Standard of Review

Based upon differing views of the evidence presented to the trial court, the parties urge disparate standards of review to govern this appeal. *1100 After reviewing the record, we agree with appellant that the trial court’s interpretation of the insurance policies in this case is subject to de novo review.

The interpretation of an insurance contract, as with that of any written instrument, is primarily a judicial function.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Janney v. CSAA Insurance Exchange
California Court of Appeal, 2021
Gilkyson v. Disney Enterprises, Inc.
California Court of Appeal, 2021
Tayefeh v. Kern Medical Center CA5
California Court of Appeal, 2020
Peterson v. Lusk (In re Lusk)
589 B.R. 678 (E.D. California, 2018)
Tierney v. Javaid
California Court of Appeal, 2018
Sharp v. Essex Insurance (In re C.M. Meiers Co.)
527 B.R. 388 (C.D. California, 2015)
Ginsberg v. Gamson
205 Cal. App. 4th 873 (California Court of Appeal, 2012)
Reynolds v. Allstate Ins.
855 F. Supp. 2d 989 (N.D. California, 2012)
President & Fellows of Harvard College v. Westchester Fire Insurance
28 Mass. L. Rptr. 113 (Massachusetts Superior Court, 2011)
Arce v. Kaiser Foundation Health Plan, Inc.
181 Cal. App. 4th 471 (California Court of Appeal, 2010)
Flintkote Co. v. General Accident Assurance Co.
410 F. Supp. 2d 875 (N.D. California, 2006)
Lockheed Martin Corp. v. Continental Insurance
35 Cal. Rptr. 3d 799 (California Court of Appeal, 2005)
McKinley v. XL Specialty Insurance
33 Cal. Rptr. 3d 98 (California Court of Appeal, 2005)
Safeco Ins. Co. of America v. Parks
19 Cal. Rptr. 3d 17 (California Court of Appeal, 2004)
Jordan v. Allstate Insurance
11 Cal. Rptr. 3d 169 (California Court of Appeal, 2004)
Corby v. Gulf Insurance
8 Cal. Rptr. 3d 663 (California Court of Appeal, 2004)
Westoil Terminals v. Industrial Indem.
1 Cal. Rptr. 3d 516 (California Court of Appeal, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
31 Cal. App. 4th 1094, 37 Cal. Rptr. 2d 508, 95 Daily Journal DAR 1109, 95 Cal. Daily Op. Serv. 652, 1995 Cal. App. LEXIS 48, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cooper-companies-inc-v-transcontinental-insurance-calctapp-1995.